C
igarette smoking is an important stroke risk factor: smoking increases the risk of stroke by approximately 50%. 1 Stroke risk increases with increasing cigarette consumption. 2 The mechanism of the increased stroke risk has been attributed to both procoagulant and atherogenic effects of smoking. 3, 4 Analysis of the landmark National Institutes of Health (NIH) tissue plasminogen activator (tPA) trial has shown that cigarette smoking protects tPA-treated patients from cerebral hemorrhage. 5 , 6 The prevalence of intracerebral hemorrhage among smokers receiving tPA was 4%, as compared with 13% of the patients who did not smoke. This observation is especially relevant because the therapeutic benefits of tPA in acute stroke are partially outweighed by a more than a sixfold increased risk of symptomatic intracerebral hemorrhage. 5 , 6 The mechanism of this dual role for smoking (increasing the risk for stroke while protecting from hemorrhage in the setting of acute stroke therapy) has been unclear. One possible mechanism involves smoking modulation of fibrinolysis, which requires the conversion of plasminogen into plasmin by tPA. tPA is rapidly inactivated by plasminogen
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activator inhibitor-1 (PAI-1), the predominant plasminogen activator inhibitor in human plasma. [7] [8] [9] PAI-1 is synthesized by endothelial cells (ECs), human hepatocytes, granulosa, and vascular smooth muscle cells and comprises up to 12.5% of the protein secreted by ECs in culture. 9, 10 Increased plasma PAI-1 is found in patients with ischemic stroke, 11 in survivors of myocardial infarction, 12, 13 and in other thrombotic disorders. 14 -17 In the present study we investigated the relationship between PAI-1 and nicotine, an important component of cigarette smoke. This is particularly relevant because nicotine has previously been shown to alter rat brain capillary endothelial fibrinolysis and to increase infarct size in a middle cerebral artery occlusion model. 18 Our results here demonstrate that concentrations of nicotine achieved in the plasma/ serum of smokers increase PAI-1 production by central nervous system (CNS)-EC. The protein kinase C (PK-C) pathway was chosen for investigation because it is a common intracellular signal transduction mechanism and therefore would be relevant to understanding the regulation of PAI-1 production.
Materials and Methods

Cell Culture
CNS-ECs were derived from human brain as previously described in detail. 19 Cells were cultured in RPMI-1640 medium (GIBCO Labs) supplemented with 100 ng/mL endothelial cell growth factor Endogro (VECTEC), 2 mmol/L L-glutamine, 10 mmol/L Hepes, 24 mmol/L sodium bicarbonate, 300 USP U of heparin, 1% penicillin/streptomycin, and 10% fetal calf serum. We used subconfluent preparations of cells up until passage 4 to 5 only; and Endogro-free medium was used beginning 24 hours before the experiment. The purity of CNS-EC (Ͼ95%) was confirmed by immunocytochemical staining for factor VIII, glial fibrillary acidic protein, and the macrophage maker CD11b, as previously described. 19 The PK-C inhibitor GF-109203-X (GF) (Calbiochem) was added to the cells 30 minutes before nicotine treatment. GF at 1 mol/L was used in inhibition experiments; this dose completely inhibited PK-C in CNS-EC without affecting cell viability (authors' unpublished observations). Nicotine sulfate (Sigma) was used at 100 nmol/L, on the basis of titration experiments and physiological range.
PK-C Assay
ECs were treated as described in the previous sections. The PK-C assays were performed using PK-C assay kits obtained from GIBCO. Briefly, the experimental treatments were terminated by replacing the medium with the cell extraction buffer (20 mmol/L TRIS, 0.5 mmol/L EDTA, 0.5 mmol/L EGTA, 25 g/mL each aprotinin and leupeptin, pH 7.5) at room temperature. The cells were then homogenized with a precooled Dounce homogenizer, and the cytosol and membrane fractions were separated by centrifugation (10 000g, 30 minutes), at 4°C. The supernatants were collected as the cytosol fraction. The pellets were resuspended in 0.5 mL extraction buffer with the detergent (1% NP-40). Membrane fractions were obtained by centrifugation (10 000g, 10 minutes, 4°C) and the supernatant was collected. The determinations of PK-C activity in the cytosol and membrane fractions were performed according to the manufacturer's instructions. The specific PK-C substrate was a synthetic peptide from myelin basic protein (amino acids 4 to 14) with an acetylated N-terminal glutamine, and the specific inhibitor was a peptide (amino acids 19 to 36) derived from the same protein that binds to the "pseudosubstrate" region of the regulatory domain. The specific PK-C activity was determined as the difference between phosphorylation of the PK-C-specific substrate in the absence or presence of the specific PK-C inhibitor. The data are presented as ratios of the membrane and the total (cytosolϩmembrane) PK-C activities.
PAI-1 Production
PAI-1 production was evaluated using the commercially available ELISA kit (American Diagnostics Inc). Briefly, cells were grown in culture to 70% to 80% confluence in 10% fetal calf serum. Culture supernatants (100 L) were removed after 24, 48, 72, and 96 hours and evaluated for PAI-1 content. The ELISA determined the amounts of bound and free PAI-1 present. Each data point was generated by samples run in triplicate; and each experiment was repeated at least 3 times.
RNA Analysis
RNA from 2 to 3ϫ10 6 cultured cells was isolated 24 hours after treatment and prepared according to a modification of the acid phenol method using the Trisol reagent (Life Technologies) as specified by the manufacturer. Twelve micrograms of total RNA was denatured and fractionated on a 1.2% agarose gel containing formaldehyde, then transferred to Hybond-N ϩ nylon membrane (Amersham), and hybridized with [ 32 P]dCTP Klenow-labeled randomprimed probes (Boehringer Mannheim) according to manufacturer's instructions. Prehybridization was performed in Quikhyb hybridization solution (Stratagene) for 15 minutes at 68°C. Subsequently the labeled probe plus 1 mg salmon sperm DNA was added to the hybridization solution mixture and incubated for 1 hour at 68°C. The hybridized membrane was washed twice with 2ϫ standard saline citrate, 0.1% sodium dodecyl sulfate at 37°C, then washed with 0.1ϫ standard saline citrate, 0.1% sodium dodecyl sulfate buffer for 15 minutes at 60°C. Membranes were exposed to Hyperfilm-MP (Amersham) for at least 24 hours at Ϫ70°C. The human PAI-1 probe used in hybridization, obtained from plasmid designated as pPAI-1 1.3, is 1253 bp in length 20 and binds to the full-length PAI-1 mRNA (3.0 kb). Densities of hybridized bands were determined by scanning and analyzed using the NIH Image software program. Blots were rehybridized with labeled polymerase chain reaction products of glyceraldehyde-3 phosphate dehydrogenase (GAPDH; Stratagene), the housekeeping gene, to control for total amount of RNA present in the cells and precision of RNA loading.
Statistics
All experiments were performed 3 times unless otherwise stated. The error bars on all figures correspond to SEM. Statistical comparisons between groups were performed using unpaired Student's t tests or 2-way ANOVA. All data presented as significant in this study have the value of PϽ0.02, unless otherwise indicated.
Results
We investigated the effects of physiological concentrations of nicotine on PAI-1 production by human brain-derived endothelial cells. CNS-ECs were cultured in the absence or presence of nicotine (100 nmol/L) for 96 hours. Aliquots of supernatant were removed after 24, 48, 72 and 96 hours and analyzed for secreted PAI-1 protein using the ELISA technique. The results of 4 experiments (each in triplicate) on different CNS-EC primary cell cultures demonstrated a significant increase in PAI-1 production following nicotine treatment after 72 hours with a continued increase through 96 hours of culture. Primary cultures typically exhibit great variability in baseline levels of PAI-1 production, ranging from 9.6 to 33.4 g/mL per 10 6 cells (27.1Ϯ2.9; SEM), and after 72 hours of nicotine treatment, ranging from 31.8 to 75.2 g/mL per 10 6 cells (53.8Ϯ5.8; SEM). The results of nicotine treatment were therefore assessed in terms of relative PAI-1 production for each treated culture as compared with its respective control. Nicotine treatment increased relative PAI-1 production by 1.9Ϯ0.2 fold (PϽ0.02). To determine whether nicotine affects PAI-1 mRNA expression, CNS-ECs were exposed to nicotine for 24 hours, and RNA was isolated and analyzed for PAI-1 mRNA. The results ( Figure 1A, 1B) show that PAI-1 mRNA was increased approximately twofold in the presence of nicotine. The data presented are representative of 3 experiments performed. Incubation with nicotine for 1, 4, or 6 hours showed no significant increase in PAI-1 mRNA above control values (data not shown). Thus, nicotine increases PAI-1 production on mRNA and protein levels. In contrast, incubation of the CNS-ECs with nicotine (100 nmol/L) for 72 hours did not significantly affect tPA production (14.4Ϯ1.7 ng/mL ⅐ 10 6 cells for the control versus 15.5Ϯ1.6 ng/mL ⅐ 10 6 cells for nicotine-treated cells). We next determined whether the PK-C-associated intracellular signal transduction pathway is involved in a nicotineinduced increase in PAI-1 production. The effect of nicotine on PK-C activity was measured as a function of time. Figure  2 shows that nicotine (100 nmol/L) indeed caused an increase in PK-C activity in ECs. The increase in PK-C activity was significant within 30 seconds, attained maximum levels at 2 minutes, and sharply declined thereafter, reaching control levels at 30 minutes (Figure 2) . To determine the significance of the nicotine-induced PK-C activation in the observed increase in PAI-1 production, we measured the effect of nicotine in the presence of the PK-C inhibitor GF. Figure 1 demonstrates that in the presence of GF, nicotine has no effect on PAI-1 mRNA levels. Similar results were obtained with another PK-C inhibitor calphostin C (data not shown). Furthermore, Figure 3 shows that GF completely inhibited nicotine-induced PAI-1 protein production, demonstrating that in CNS-ECs PAI-1 mRNA expression and protein production are dependent on the activation of PK-C.
Discussion
We have shown that nicotine increases PAI-1 production by human CNS-ECs. After 72 hours of incubation, PAI-1 protein production increased twofold; this paralleled the increase in PAI-1 mRNA expression. These effects were completely abolished by inhibition of PK-C, indicating that nicotine induces increased PAI-1 production in CNS-ECs via a PK-C-dependent pathway.
We observed the effects of nicotine at 100 nmol/L, within the concentration range of nicotine achieved in the serum of smokers. 21, 22 Previous studies of the biological effects of nicotine in various vascular systems have shown that mice chronically exposed to nicotine exhibit subendothelial edema, endothelial cell swelling, cytoplasmic vacuolation, and mitochondrial swelling. 23 Exposure of bovine EC to nicotine caused giant cell formation, ruffled membrane, and extensive cellular vacuolation. 24, 25 Other studies found no significant effects of nicotine on EC at the submicromolar concentrations. No change of functions such as growth properties, morphology, total protein and collagen synthesis and turnover, lactate production, DNA synthesis, and platelet-subendothelial interaction/adhesion was observed in bovine aortic ECs with up to 10 Ϫ4 mol/L nicotine in 1 to 4 days. 26 Thus, there is no consensus in the literature regarding the effects of nicotine on ECs.
This uncertainty may be related to the use of different nicotine concentrations and duration of the treatment and may depend on the target tissue. Specifically, there are significant physiological differences between micro-and macrovascular ECs. Several growth factors are specific for one or the other type. [27] [28] [29] Coagulation factors are expressed differently between large vessels and capillaries. Thrombin stimulates ECs from large vessels but not from the capillaries. 30 Elevation of glucose resulted in decreased PAI-1 mRNA in brain ECs but not in human umbilical vein ECs (HUVECs) or bovine aortic ECs. 31 The PK-C activator PMA suppresses the basic fibroblast growth factor-induced proliferation of capillary ECs but has no effect on aortic ECs. 32 Also, vanadate treatment leads to an inhibition of protein tyrosine kinase activity in the aortic ECs but not in the capillary ECs. 33 Thus, these ECs differ not only in the array of growth factor receptors present on their Effect of PK-C inhibitor GF on nicotine-induced PAI-1 production. Cultures of CNS-EC were exposed to nicotine (100 nmol/L), GF (1 mol/L), or both reagents for 72 hours. Subsequently supernatants were tested for PAI-1 production (per 10 6 cells) using the ELISA technique. Nicotine significantly increased PAI-1 production (PϽ0.02). In the presence of GF, there was no significant difference between nicotine-treated and control cells.
surfaces but also in their intracellular regulatory mechanisms. For these reasons we have used human adult CNS-derived ECs, emphasizing the relevance to stroke. Our results, which associated increased PAI-1 production with activation of PK-C, agree with other studies in which PK-C activation was shown to increase PAI-1 production in various ECs, including HUVECs, 9,34 -36 bovine CNS-ECs, 31 and bovine aortic ECs. 31, 37 Furthermore, our data are consistent with clinical findings showing increased plasma levels of PAI-1 in smokers. 38, 39 There is a complex relationship between smoking and hemorrhagic transformation after tPA treatment for stroke. Hemorrhagic transformation is related to disruption of the microvascular basal lamina after cerebral ischemia, 40 and it is unclear how that process is modified by therapeutic thrombolysis and smoking. However, it is known that smokers have increased plasma levels of PAI-1, 38 and there is substantial evidence emphasizing the importance of PAI-1 in thrombolysis after acute myocardial infarction. Measurements of PAI-1 predict outcome in these patients: high baseline PAI-1 levels are associated with occluded coronary arteries 90 minutes after treatment. 41 Moreover, neutralizing antibodies to PAI-1 produce enhanced efficacy of therapeutic thrombolysis in an experimental model of coronary artery thrombosis. 42 In the setting of acute arterial thrombosis, endothelial-and platelet-derived PAI-1 bind to fibrin strands and inactivate tPA. [42] [43] [44] It should be emphasized that nicotine is only one component of cigarette smoke. It is thought that much of the toxic effects of smoking are due to a variety of gas-phase constituents and to tar rather than nicotine. 45 It is unclear to what extent nicotine contributes to hemostatic alterations in humans. Subjects receiving transdermal or oral nicotine have plasma levels of platelet activation products (␤-thromboglobulin and platelet factor 4) and von Willebrand factor that tend to be intermediate between smokers and control subjects, 46, 47 suggesting possible synergistic effects among the different cigarette components. With the use of our in vitro culture system, the effects of nicotine alone on brain-derived ECs are evident.
In summary, our results demonstrate that nicotine induces PAI-1 production in CNS-ECs and that this process is mediated through the PK-C-dependent pathway. Enhanced production of PAI-1 may serve to increase stroke risk by increasing predisposition to thrombosis and to reduce hemorrhagic risk by inactivating therapeutic tPA. Thus, clarification of the mechanism of PAI-1 regulation by nicotine may allow therapeutic modification of both harmful and potentially useful effects.
